| Name | Title | Contact Details |
|---|
SteadyMed Therapeutics, Inc. is a Specialty Pharmaceutical Company. SteadyMed leverages its PatchPump platform to develop its own therapeutic portfolio and partners to optimize the delivery of high volume (greater than two mL), high value, small molecule or biologic drugs. Our family of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner. SteadyMed aspires to redefine the parenteral therapeutics experience for patients dependent upon large doses of intravenous and subcutaneous medications: Extending the limits of parenteral therapeutics to restore freedom, joy and dignity to patients’ lives.
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for our patients. Cytrellis` first product, the ellacor® System with Micro-Coring™ Technology, is indicated for use by medical professionals for the treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Ellacor provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin and to help restore youthful beauty.
Accurate Biomed Services is a Bethany, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.
Lumenis, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.